舒血宁注射液与奥扎格雷钠联合治疗对脑梗死患者血清IGF-1、HIF-1α和ICAM-1水平的影响

Effects of Shuxuening Injection Combined with Ozagrel Sodium on Serum IGF-1,HIF-1α and ICAM-1 Levels in Patients with Cerebral Infarction

目的探讨舒血宁注射液与奥扎格雷钠联合治疗对脑梗死患者血清类胰岛素一号增长因子(IGF-1)、缺氧诱导因子-1α(HIF-1α)及细胞间黏附分子-1(ICAM-1)水平的影响。方法选取2014年1月-2016年10月我院收治的92例脑梗死患者作为研究对象,按入院顺序将其分为对照组和观察组,对照组患者在脑梗死其他常规治疗上予以奥扎格雷钠治疗,观察组患者在对照组基础上加用舒血宁注射液治疗,治疗结束后比较两组患者间IGF-1、HIF-1α、ICAM-1、C反应蛋白(CRP)水平及美国国立卫生研究院卒中量表(NIHSS)评分的差异,并记录所有患者治疗后的临床效果及治疗过程中不良反应的发生情况。结果两组患者治疗前其IGF-1、HIF-1α、ICAM-1及CRP水平和NIHSS评分均无明显差异(P>0.05),治疗后两组患者其IGF-1水平较治疗前升高,而HIF-1α、ICAM-1及CRP水平和NIHSS评分均较治疗前降低,且观察组较对照组升高或降低程度明显(P<0.05);观察组临床总有效率(95.65%)明显高于对照组(78.26%),(P<0.05);两组患者不良反应的发生率比较无明显差异(P>0.05)。结论舒血宁联合奥扎格雷钠可明显升高脑梗死患者IGF-1水平和降低HIF-1α、ICAM-1、CRP水平及NIHSS评分,且无明显严重不良反应,可作为临床上治疗脑梗死患者的一种优选方案。

Objective To investigate the influence of Shuxuening injection combined with ozagrel sodium on levels of serum insulin-like growth factor-1（ IGF-1）,hypoxia-inducible factor-1α（ HIF-1α） and intercellular adhesion molecule-1（ ICAM-1）.Methods A total of 92 patients with cerebral infarction treated at our hospital between January 2014 and October2016 were divided into two groups： the control group and the observation group. The cerebral infarction patients in the control group were treated with ozagrel sodium routines while the observation group was treated with Shuxuening injection combined with ozagrel sodium.The levels of IGF-1,HIF-1α,ICAM-1,C-reactive protein（ CRP） and NIHSS score in the observation group were compared with those in the control group.The clinical effect of each patient after treatment and the incidence of adverse reactions during treatment were recorded in the two groups.Results There was no significant difference in IGF-1,HIF-1α,ICAM-1,CRP level or NIHSS scores between the two groups before treatment（ P 0. 05）.After treatment,IGF-1 levels in the two groups were higher（ P 0. 05）.The levels of HIF-1α,ICAM-1,CRP and NIHSS in the observation group were significantly lower than those of the control group（ P 0. 05）. The total effective rate of the observation group（ 95. 65%） was significantly higher than that of the control group（ 78. 26%）,（ P〈0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（ P 0. 05）.Conclusion Shuoxuening injection combined with ozagrel sodium can significantly increase the levels of IGF-1 and reduce the levels of HIF-1α,ICAM-1,CRP and NIHSS in patients with cerebral infarction,and there are no serious adverse reactions.It can be used as a preferred program in clinical treatment of cerebral infarction patients.